human plasma proteins: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
human plasma proteins: clinical details
Prescribing considerations
- Confirm the licensed indication and use a specific coagulation-factor concentrate when available and appropriate.
- Select an ABO-compatible presentation and record the product name and batch number for traceability.
- Assess previous plasma reactions, thrombotic risk, cardiac function, pulmonary oedema and sodium burden.
- Transmission of infectious agents cannot be completely excluded despite donor screening and pathogen-reduction measures.
- Data in children and adolescents are limited.
Contraindications and cautions
- IgA deficiency with documented anti-IgA antibodies.
- Hypersensitivity to human plasma proteins, excipients or manufacturing residues.
- Severe protein S deficiency.
Monitoring
- Monitor clinical haemostasis and relevant coagulation tests.
- Observe for allergic, respiratory, haemolytic, thrombotic and circulatory-overload reactions.
- Monitor ionised calcium where citrate toxicity is a concern, particularly during paediatric plasma exchange.
- Passively transferred plasma components can cause misleading laboratory results, including a false-positive pregnancy test.
Clinical pharmacology
This solvent-detergent-treated pooled plasma contains functional coagulation factors, natural inhibitors, albumin and immunoglobulins. Its pharmacokinetic behaviour is similar to fresh-frozen plasma, although protein S activity is lower than in normal plasma.
Formulation and product differences
- Frozen solution for intravenous infusion, supplied in separate blood-group A, B, AB and O presentations.
- Contains sodium citrate dihydrate, sodium dihydrogen phosphate dihydrate and glycine.
- Must be thawed using a validated method, inspected before use and never refrozen.
human plasma proteins interactions
No medicine interactions have been identified, but important intravenous incompatibilities apply.
Calcium-containing intravenous solutions
Do not administer through the same intravenous line because clot formation may occur.
Other intravenous medicines
Do not mix in the same container because proteins may be inactivated or precipitate.
Red blood cells or platelets
They may be given compatibly only when the ABO compatibility of both preparations is respected.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.